cedazuridine-decitabine
Selected indexed studies
- Cedazuridine/decitabine: from preclinical to clinical development in myeloid malignancies. (Blood Adv, 2021) [PMID:33904891]
- Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study. (Blood, 2020) [PMID:32285126]
- Cedazuridine. (, 2006) [PMID:33355729]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Cedazuridine/decitabine: from preclinical to clinical development in myeloid malignancies. (2021) pubmed
- Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study. (2020) pubmed
- Cedazuridine. (2006) pubmed
- Oral therapy for myelodysplastic syndromes/neoplasms and acute myeloid leukemia: a revolution in progress. (2023) pubmed
- Role of cedazuridine/decitabine in the management of myelodysplastic syndrome and chronic myelomonocytic leukemia. (2021) pubmed
- The development and clinical use of oral hypomethylating agents in acute myeloid leukemia and myelodysplastic syndromes: dawn of the total oral therapy era. (2021) pubmed